For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

PGP92

4466MW

Dr.Ranjith Kumar C R
Membership No Author Name Email Mobile
4466MW Dr.Ranjith Kumar C R ranjithrp963@gmail.com 9148049510
Medical Retina and Uvea

Beyond the Occlusion – Bevacizumab and Macular Recovery in BRVO.

Purpose :
To evaluate the anatomical outcomes of intravitreal bevacizumab in patients with macular edema secondary to BRVO.
Methods :
Intravitreal bevacizumab (1.25 mg/0.05 mL) was given in the inferotemporal quadrant under aseptic precautions for 3 consecutive months. Post-injection, patients were followed up for 3 consecutive months.
CMT (in µm) was measured using OCT at baseline and after intravitreal bevacizumab at 1 month, 2 months, and 3 months.
Results:
12 patients were included in the study, which included 8 male patients and 4 female patients.Baseline mean CMT was 422 ± 32 µm before intravitreal bevacizumab injection. The mean CMT at 3 months was 288 ± 16 µm after 3 doses of intravitreal bevacizumab injection.
Conclusion:
Intravitreal bevacizumab provides significant anatomical and functional improvement in patients with macular edema secondary to BRVO, supporting its role as an effective treatment option.

Membership No Author Name Email Mobile
4392 Dr.Pawan Gampa Kumar drpawangampa@gmail.com 8861213079
4464MW Dr.Sakshi gupta gupta.sakshi161998@gmail.com 9034237226